300 related articles for article (PubMed ID: 33121497)
1. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study.
Zhang J; Hao Y; Ou W; Ming F; Liang G; Qian Y; Cai Q; Dong S; Hu S; Wang W; Wei S
J Transl Med; 2020 Oct; 18(1):406. PubMed ID: 33121497
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
[TBL] [Abstract][Full Text] [Related]
3. Effective treatment of severe COVID-19 patients with tocilizumab.
Xu X; Han M; Li T; Sun W; Wang D; Fu B; Zhou Y; Zheng X; Yang Y; Li X; Zhang X; Pan A; Wei H
Proc Natl Acad Sci U S A; 2020 May; 117(20):10970-10975. PubMed ID: 32350134
[TBL] [Abstract][Full Text] [Related]
4. Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study.
Masiá M; Fernández-González M; Padilla S; Ortega P; García JA; Agulló V; García-Abellán J; Telenti G; Guillén L; Gutiérrez F
EBioMedicine; 2020 Oct; 60():102999. PubMed ID: 32950003
[TBL] [Abstract][Full Text] [Related]
5. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
7. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
[TBL] [Abstract][Full Text] [Related]
8. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.
Canziani LM; Trovati S; Brunetta E; Testa A; De Santis M; Bombardieri E; Guidelli G; Albano G; Folci M; Squadroni M; Beretta GD; Ciccarelli M; Castoldi M; Lleo A; Aghemo A; Vernile L; Malesci A; Omodei P; Angelini C; Badalamenti S; Cecconi M; Cremonesi A; Selmi C;
J Autoimmun; 2020 Nov; 114():102511. PubMed ID: 32713677
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.
Rossotti R; Travi G; Ughi N; Corradin M; Baiguera C; Fumagalli R; Bottiroli M; Mondino M; Merli M; Bellone A; Basile A; Ruggeri R; Colombo F; Moreno M; Pastori S; Perno CF; Tarsia P; Epis OM; Puoti M;
J Infect; 2020 Oct; 81(4):e11-e17. PubMed ID: 32652164
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study.
Patel A; Shah K; Dharsandiya M; Patel K; Patel T; Patel M; Reljic T; Kumar A
Indian J Med Microbiol; 2020; 38(1):117-123. PubMed ID: 32719218
[TBL] [Abstract][Full Text] [Related]
12. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
Ip A; Berry DA; Hansen E; Goy AH; Pecora AL; Sinclaire BA; Bednarz U; Marafelias M; Berry SM; Berry NS; Mathura S; Sawczuk IS; Biran N; Go RC; Sperber S; Piwoz JA; Balani B; Cicogna C; Sebti R; Zuckerman J; Rose KM; Tank L; Jacobs LG; Korcak J; Timmapuri SL; Underwood JP; Sugalski G; Barsky C; Varga DW; Asif A; Landolfi JC; Goldberg SL
PLoS One; 2020; 15(8):e0237693. PubMed ID: 32790733
[TBL] [Abstract][Full Text] [Related]
13. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.
Ramiro S; Mostard RLM; Magro-Checa C; van Dongen CMP; Dormans T; Buijs J; Gronenschild M; de Kruif MD; van Haren EHJ; van Kraaij T; Leers MPG; Peeters R; Wong DR; Landewé RBM
Ann Rheum Dis; 2020 Sep; 79(9):1143-1151. PubMed ID: 32719045
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis.
Mojtabavi H; Saghazadeh A; Rezaei N
Eur Cytokine Netw; 2020 Jun; 31(2):44-49. PubMed ID: 32933891
[TBL] [Abstract][Full Text] [Related]
15. Preemptive interleukin-6 blockade in patients with COVID-19.
Guillén L; Padilla S; Fernández M; Agulló V; García JA; Telenti G; García-Abellán J; Botella Á; Gutiérrez F; Masiá M
Sci Rep; 2020 Oct; 10(1):16826. PubMed ID: 33033405
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
Mikulska M; Nicolini LA; Signori A; Di Biagio A; Sepulcri C; Russo C; Dettori S; Berruti M; Sormani MP; Giacobbe DR; Vena A; De Maria A; Dentone C; Taramasso L; Mirabella M; Magnasco L; Mora S; Delfino E; Toscanini F; Balletto E; Alessandrini AI; Baldi F; Briano F; Camera M; Dodi F; Ferrazin A; Labate L; Mazzarello G; Pincino R; Portunato F; Tutino S; Barisione E; Bruzzone B; Orsi A; Schenone E; Rosseti N; Sasso E; Da Rin G; Pelosi P; Beltramini S; Giacomini M; Icardi G; Gratarola A; Bassetti M
PLoS One; 2020; 15(8):e0237831. PubMed ID: 32817707
[TBL] [Abstract][Full Text] [Related]
17. Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19.
Nakamura H; Miyagi K; Otsuki M; Higure Y; Nishiyama N; Kinjo T; Nakamatsu M; Haranaga S; Tateyama M; Fujita J
Intern Med; 2020 Nov; 59(22):2945-2949. PubMed ID: 32963155
[TBL] [Abstract][Full Text] [Related]
18. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.
Morena V; Milazzo L; Oreni L; Bestetti G; Fossali T; Bassoli C; Torre A; Cossu MV; Minari C; Ballone E; Perotti A; Mileto D; Niero F; Merli S; Foschi A; Vimercati S; Rizzardini G; Sollima S; Bradanini L; Galimberti L; Colombo R; Micheli V; Negri C; Ridolfo AL; Meroni L; Galli M; Antinori S; Corbellino M
Eur J Intern Med; 2020 Jun; 76():36-42. PubMed ID: 32448770
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab treatment in COVID-19: A single center experience.
Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J
J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759
[TBL] [Abstract][Full Text] [Related]
20. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
